Kala Visvanathan

605 posts

Kala Visvanathan banner
Kala Visvanathan

Kala Visvanathan

@kalavisvanathan

Oncologist Epidemiologist,Cancer Genetics | passionate about cancer prevention, improving outcomes for survivors, mentoring & DEI. Love a laugh.Tweets my own

Baltimore, MD Katılım Nisan 2017
1K Takip Edilen461 Takipçiler
Kala Visvanathan retweetledi
Jen Heemstra
Jen Heemstra@jenheemstra·
Great mentors expand your capacity while also sharpening your focus. They help you to see all of the things that you’re capable of doing while also helping you to choose which of those things are worth pursuing.
English
8
97
481
35.5K
Kala Visvanathan retweetledi
Karen Bandeen-Roche
Karen Bandeen-Roche@BandeenKaren·
Just thanks as I've ended as the @jhubiostat Chair. Dear department friends-so many of you being with me at my farewell meant so much; same to JHU friends & family. Feeling truly privileged as I paddle into the sunset (photo authentic!) of chair life relishing my & dept's future!
Karen Bandeen-Roche tweet media
English
2
10
102
8.7K
Kala Visvanathan retweetledi
Kristy A. Brown, PhD
Kristy A. Brown, PhD@BrownLab_KUMC·
The Brown Lab is moving to KUMC! This fantastic opportunity will allow me to work with the @KUcancercenter and the @KUDiabetesInst to build research efforts to decipher the etiology of #obesity-related #cancers and identify new risk reduction strategies.
Kristy A. Brown, PhD tweet media
English
25
14
130
21.4K
Kala Visvanathan retweetledi
Reshma Jagsi
Reshma Jagsi@reshmajagsi·
The Nat’l Academies @nasem wants to understand how to promote equity for STEMM professionals w/caregiving responsibilities outside of work, especially caregivers of color. Check out survey.rti.org/se/1/care/ if you’d be willing to be interviewed (via Zoom)!
English
0
11
17
4.5K
Kala Visvanathan retweetledi
Denis Wirtz
Denis Wirtz@deniswirtz·
We have created a database of funding opportunities for early-career faculty/researchers in oncology/cancer research. For each of the 86 opportunities, we provide a description, link, $ amount, deadline, and eligibility criteria. Download for free here: research.jhu.edu/rdt/funding-op…
Denis Wirtz tweet media
English
3
143
361
73.1K
Kala Visvanathan retweetledi
GRASP
GRASP@GRASPtweets·
A few advocate spots remain for GRASP discussions of work presented at #ASCO23 to take place on June 14 & 15. These are virtual, small-group discussions between scientists & patients, with six time options. Sign up for an account & register for a session! graspcancer.org/events/asco23/
English
0
5
4
1.9K
Kala Visvanathan retweetledi
Aditya Bardia, MD
Aditya Bardia, MD@dradityabardia·
HER2 Testing: ASCO-CAP Guideline Update. Imp and helpful commentary ⁦@awolff⁩ - at that low level, IHC is really sensitive to subtle analytic factors. A slide sitting unstained for a week or so might change a 1+ to a 0 result. #bcsm sites.libsyn.com/115284/her2-te…
English
2
10
29
5.9K
Kala Visvanathan retweetledi
Dana-Farber News
Dana-Farber News@DanaFarberNews·
Researchers from @DanaFarber Cancer Institute have found a way to detect an increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, opening the door to more affordable, accessible tests. dana-farber.org/newsroom/news-…
Dana-Farber News tweet media
English
1
18
60
7K
Kala Visvanathan retweetledi
Tatiana Prowell, MD
Tatiana Prowell, MD@tmprowell·
#ASCO23 Dr. @BarYaelMD shows that if we biopsy enough times, we’ll get a HER2-low (83% after 3 bx & 100% after 5 bx in this dataset). Is this just sampling or true evolution? We don’t know (or if the answer even matters. Include pts w/ marker-neg tumors in early drug dev.) #bcsm
Tatiana Prowell, MD tweet mediaTatiana Prowell, MD tweet mediaTatiana Prowell, MD tweet mediaTatiana Prowell, MD tweet media
English
1
17
38
5.3K

Keşfet

@fyzashaikh @alisongemmill @jhubiostat @KUcancercenter @KUDiabetesInst @nasem @awolff @DanaFarber